Israeli biomed company Evogene, which genetically engineers plant seeds, is in talks to go public on Nasdaq at a company value of $250 million. Calcalist reports that the IPO will be led by Deutsche Bank and Credit Swiss. Evogene is currently being traded in the Tel Aviv stock exchange at a company value of $210 million.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

UN Honors Israeli Food Exec For Sustainability Work
September 26, 2023

Startup Unveils Tech To Speed Up Growth Of Cultivated Meat
September 26, 2023

Israel Invests Millions To Help AI Comprehend Hebrew, Arabic
September 21, 2023

Cybersecurity Startup Cato Raises $238M With $3B Valuation
September 21, 2023
Facebook comments